NEWS DETAIL

ReForm Biologics Names Neal Muni, MD, MSPH, Executive Vice President and Chief Operating Officer

- ReForm continues to rapidly expand experienced management team -

September 14, 2021 07:00 AM Eastern Daylight Time

WOBURN, Mass.--(BUSINESS WIRE)--ReForm Biologics, Inc., a company developing a new generation of innovative biologic medicines to improve patient access, safety, and convenience, today announced the appointment of Neal Muni, MD, MSPH, as Executive Vice President and Chief Operating Officer.

“Dr. Muni has had a storied career in the life sciences sector,” said Jeff Hackman, President and Chief Executive Officer at ReForm Biologics. “Over the course of the past 20 years, Neal has been successful in all stages of drug discovery, development, and commercialization. During this time, Neal has maintained staff appointments at Harvard Medical School and its teaching hospitals, which has fueled his passion for improving patient care. His extraordinarily broad and deep experience in the growth and evolution of life science companies will be invaluable as ReForm develops our own pipeline of biologics that can improve care for fragile patients. On behalf of all of us here, we welcome Neal to ReForm.”

“As a physician, I have a profound appreciation for the challenges of treating fragile patients such as children, the elderly and patients living with neurological diseases,” said Dr. Muni. “ReForm's ability to reformulate biologics could potentially allow these patients to be treated at home or in a physician's office with a subcutaneous injection instead of a lengthy, inconvenient and often painful intravenous infusion at a clinic or hospital. I am looking forward to working with a team whose mission is to improve the way we are able to treat this vulnerable population.”

Prior to joining ReForm, Dr. Muni most recently served as the CEO of Azurity Pharmaceuticals (formerly CutisPharma). During his tenure, Dr. Muni led the transformation of CutisPharma from pharmacy distribution into a fully integrated specialty pharma, leading the acquisition of Silvergate Pharmaceuticals as well as overseeing the FDA approval and launch of two pipeline drugs, FIRVANQ® for clostridium difficile colitis and Katerzia® for pediatric hypertension.

Prior to Azurity, Dr. Muni served as the Head of New Product Planning and Corporate Strategy at Sunovion Pharmaceuticals. Before that, Dr. Muni was an engagement manager at the healthcare investment bank Leerink Swann (now SVB Leerink). He was a Medical Officer in the Division of Cardiovascular Devices at the FDA before joining Leerink. Over the past 20 years, Neal Muni has maintained staff appointments at Harvard Medical School and its teaching hospitals, including Brigham and Women's Hospital, Dana Farber Cancer Institute, and Faulkner Hospital, as well as Harvard Medical School's Wyss Institute. He received his MD as well as MSPH from the Tulane School of Medicine, and a BA in Business Economics and B.Sc. in Biochemistry from Brown University.

About ReForm Biologics, Inc.

ReForm Biologics' mission is to develop improved biologic formulations derived from our proprietary, patented technology platform to enhance patients' lives, particularly for fragile populations such as children and the elderly. We are doing this by improving the viscosity and stability of known biologics, with our own formulations as well as for those of other biopharmaceutical companies to make their medicines gentler for patients.

 

Contacts

Rob Kloppenburg
Shoreline Biotech Communications
(617) 930-5595